Agbioscience
350. Elevate Ventures’ Matt Tyner on the cost of innovation + the role of the investor in this next era of venture capital
03 Mar 2025
Pitchbook reports that of venture capital deals in 2024, roughly 30% of them were down rounds or flat, meaning their valuation of the companies either went backwards or were the same round to round. It’s a trend that will continue, so how can entrepreneurs break the cycle? Matt Tyner, managing partner of America’s most active venture capital firm – Elevate Ventures, joins today to make sense of what’s ahead and how innovators can succeed. He gets into: The current state of venture capital – and the criticality of taking a step back to understand where things sit today Investors’ increased focus on profitability and not being able to cut your way to growth Artificial intelligence as an enabler – not a vertical Does the future include a shift to debt versus venture The cost of innovation and the role of an investor in this era of venture capital What the current conversation with portfolio companies looks like for Elevate Ventures What Matt sees as emerging trends in agbioscience The most important jobs to be done in the industry
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
NPR News: 12-08-2025 2AM EST
08 Dec 2025
NPR News Now
NPR News: 12-07-2025 11PM EST
08 Dec 2025
NPR News Now
NPR News: 12-07-2025 10PM EST
08 Dec 2025
NPR News Now
Meidas Health: AAP President Strongly Pushes Back on Hepatitis B Vaccine Changes
08 Dec 2025
The MeidasTouch Podcast
Democrat Bobby Cole Discusses Race for Texas Governor
07 Dec 2025
The MeidasTouch Podcast
Fox News Crashes Out on Air Over Trump’s Rapid Fall
07 Dec 2025
The MeidasTouch Podcast